一名非小细胞肺癌患者中与阿法替尼相关的应激性心肌病：病例报告
Takotsubo cardiomyopathy Afatinib-related in a non-small cell lung cancer patient: Case report.
作者信息
Ramos German E, Caglevic Christian, Bulnes Juan F, Panay Sergio E, Zapata Mario I, Daniele Andrés J, Rodríguez Manuel E
机构信息
Department of Cardiology, Instituto Oncológico Fundación Arturo López Pérez, Santiago, Chile.
Ehocardiography Laboratory, Instituto Oncológico Fundación Arturo López Pérez, Santiago, Chile.
出版信息
Front Cardiovasc Med. 2022 Nov 22;9:1060813. doi: 10.3389/fcvm.2022.1060813. eCollection 2022.
Endothelial Growth Factor Receptor (EGFR) mutations are frequently found among NSCLC patients. Second-generation Tyrosine Kinase Inhibitor (TKI) Afatinib is frequently used in this population of patients achieving better results than cytotoxic chemotherapy in terms of survival and progression. Afatinib-related cardiotoxicity has been rarely reported. Here we comment on a clinical case of a Takotsubo Cardiomyopathy Afatinib-induced in an NSCLC patient.
内皮生长因子受体（EGFR）突变在非小细胞肺癌（NSCLC）患者中很常见。第二代酪氨酸激酶抑制剂（TKI）阿法替尼常用于这类患者，在生存和疾病进展方面比细胞毒性化疗取得更好的效果。阿法替尼相关的心脏毒性鲜有报道。在此，我们评论一例非小细胞肺癌患者由阿法替尼诱发的应激性心肌病的临床病例。
Zotero 插件